Patents by Inventor Zuyin DU

Zuyin DU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal form of dapagliflozin intermediate and preparation method therefor
    Patent number: 10836786
    Abstract: Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyOphenyl)-2-ethoxy-6-(methylhydroxyl) tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, which has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xiang Li, Jun Yu, Haizhou Yu, Jinjia Wang, Lei He, Zuyin Du
  • Dapagliflozin crystal form and preparation method and use thereof
    Patent number: 10464915
    Abstract: Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(?-D-glucopyranose-1-yl)-4?-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 5, 2019
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xiang Li, Lei He, Jun Yu, Jinjia Wang, Zuyin Du
  • CRYSTAL FORM OF DAPAGLIFLOZIN INTERMEDIATE AND PREPARATION METHOD THEREFOR
    Publication number: 20190284220
    Abstract: Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3 -(4-ethoxybenzyOphenyl)-2-ethoxy-6-(methylhydroxyl) tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, which has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 19, 2019
    Inventors: Xiang LI, Jun YU, Haizhou YU, Jinjia WANG, Lei HE, Zuyin DU
  • DAPAGLIFLOZIN CRYSTAL FORM AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20190218197
    Abstract: Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(?-D-glucopyranose-1-yl)-4?-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 18, 2019
    Inventors: Xiang LI, Lei HE, Jun YU, Jinjia WANG, Zuyin DU